Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
60 hedge funds and large institutions have $70.5M invested in Zynerba Pharmaceuticals, Inc in 2017 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 2 closing their positions.
1,450% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 2
118% more capital invested
Capital invested by funds: $32.3M → $70.5M (+$38.1M)
78% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 9
76% more funds holding
Funds holding: 34 → 60 (+26)
28% more call options, than puts
Call options by funds: $10.7M | Put options by funds: $8.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$6.69M |
| 2 |
BlackRock
New York
|
+$3.94M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.96M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.99M |
| 5 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$1.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$11.7M |
| 2 |
JGC
J. Goldman & Co
New York
|
-$376K |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$368K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$218K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$179K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
JP Morgan Chase
New York
| $10K | +$9.94K | +500 | New |
|
52
Creative Planning
Overland Park,
Kansas
| $3K | -$2.98K | -150 | -47% |
|
|
NFG
53
Next Financial Group
Houston,
Texas
| $3K | +$2.98K | +150 | New |
|
|
KTC
54
Kistler-Tiffany Companies
Berwyn,
Pennsylvania
| $2K | +$1.99K | +100 | New |
|
|
TRCT
55
Tower Research Capital (TRC)
New York
| $2K | +$1.99K | +100 | New |
|
|
PA
56
Parallel Advisors
San Francisco,
California
| $2K | +$2.38K | +120 | New |
|
|
WEC
57
Winslow Evans & Crocker
Boston,
Massachusetts
| $1.01K | +$994 | +50 | New |
|
|
WVP
58
Worth Venture Partners
Fort Lee,
New Jersey
| $1K | +$795 | +40 | New |
|
59
BNP Paribas Financial Markets
Paris,
France
| $20 | – | – | – |
|
|
VKH
60
Virtu KCG Holdings
New York
| – | -$218K | -13,986 | Closed |
|
|
CG
61
Cutler Group
San Francisco,
California
| – | -$3.97K | -200 | Closed |
|
62
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1.95K | -98 | -98% |
|
ZYNE Hedge Fund Activity: Q1 2017 in Review
60 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q1 2017, worth a combined $70.5M — up 118% from $32.3M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ZYNE positions and 2 closed out — a net gain of 29 holders — while 16 added to existing stakes and 9 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $6.69M. The largest seller was Perceptive Advisors, cutting an estimated $11.7M.
- 60 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q1 2017, up from 34 in Q4 2016.
- Funds reported $70.5M of Zynerba Pharmaceuticals, Inc stock for Q1 2017, up 118% quarter-over-quarter.
- 31 funds opened new Zynerba Pharmaceuticals, Inc positions in Q1 2017 and 2 closed out, a net change of +29 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q1 2017 was Citadel Advisors, an estimated $6.69M added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q1 2017 was Perceptive Advisors, an estimated $11.7M sold.
Based on aggregated 13F filings for Q1 2017.